I 期——用 I-131 间碘苄基胍治疗转移性类癌-猫眼课题宝

I 期——用 I-131 间碘苄基胍治疗转移性类癌

批准号：

5215612

负责人：

JON P GOCKERMAN

金额：

$0.0万

依托单位：

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/5215612

关键词：

clinical research clinical trial phase I contrast media dosage drug screening /evaluation endocrine disorder gastrointestinal neoplasms guanidines halohydrocarbon human subject human therapy evaluation iodine metastasis neoplasm /cancer chemotherapy neoplasm /cancer radionuclide therapy

项目摘要

项目成果

JON P GOCKERMAN的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This is a Phase I study for treatment with I-131 Metaiodobenzylguanidine (MIBG) in patients with metastatic carcinoid. The primary objective of the study is to determine the maximum tolerated dose of I-131 MIBG in patients with untreated metastatic carcinoid. There is documentation in the literature that patients with metastatic carcinoid that uptake MIBG can obtain at least subjective improvement in their disease related symptomatology with treatment using I-131 MIBG. The maximum tolerated dose has not yet been determined and that is the goal of the current study. We hope that higher doses will improve response, both subjectively and objectively. The most recent cohort being treated is at 400 mCi of I-131 MIBG and the one patient in this cohort, at this time is eight weeks out, has shown both subjective and objective improvement without bone marrow toxicity. This is the third cohort with dose increases at 50 mCi per cohort. No dose limiting toxicities have been seen yet. Two more subjects are needed for the current cohort and we hope to continue enrolling patients to determine a maximum tolerated dose.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文